Related Experiment Video
Updated: Sep 27, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
High D-dimer plasma concentration in systemic sclerosis patients: Prevalence and association with vascular
Sofia Furtado1,2, Bertrand Dunogué1, Georges Jourdi3,4
1Service de Médecine Interne, Centre de référence des maladies auto-immunes systémiques rares d'Ile-de-France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Descartes, Paris, France.
Insights
Elevated D-dimer levels are common in systemic sclerosis patients. These high levels correlate with increased microvascular and macrovascular complications, suggesting D-dimer as a potential risk indicator.
Area of Science:
- Rheumatology
- Hematology
- Vascular Medicine
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease characterized by microvascular and macrovascular complications.
- D-dimer, a marker of coagulation and fibrinolysis, has not been extensively studied in the context of SSc complications.
Purpose of the Study:
- To determine the frequency of elevated D-dimer plasma concentration in patients with systemic sclerosis.
- To evaluate the association between elevated D-dimer and SSc-specific microvascular and macrovascular complications.
Main Methods:
- Retrospective observational study.
- Analysis of D-dimer levels and clinical data from 214 SSc patients followed between 2010 and 2018.
- Evaluation of microvascular (digital ulcers, renal crisis, pulmonary arterial hypertension) and macrovascular complications.
Main Results:
- Elevated D-dimer was observed in 43.5% of SSc patients.
- Microvascular complications were more frequent in patients with elevated D-dimer, especially after excluding cancer/VTE history (60.5% vs 44.8%, p=0.04).
- Macrovascular complications were significantly associated with high D-dimer levels (11.8% vs 3.3%, p=0.03), and new events occurred only in this group.
Conclusions:
- High D-dimer levels are frequent in systemic sclerosis.
- Elevated D-dimer is associated with both microvascular and macrovascular complications in SSc patients, even after adjusting for confounders.
- D-dimer may serve as a valuable biomarker for predicting complications in systemic sclerosis.
Objective:
To determine the frequency of elevated D-dimer plasma concentration (>500 ng/mL) in patients with systemic sclerosis and evaluate its association with systemic sclerosis-specific microvascular and macrovascular complications.
Methods:
Retrospective observational study of patients with systemic sclerosis followed in a tertiary referral center with at least one measurement of D-dimer between 2010 and 2018.
Results:
A total of 214 patients were analyzed. Mean age at inclusion was 55.1 ± 14.7 years; 180 (84.1%) were female; 74 (34.6%) had diffuse cutaneous systemic sclerosis. Anti-Scl70 and anti-centromere antibodies were positive in 74 (34.6%) and 75 (35.0%) patients, respectively. D-dimer level was elevated in 93 (43.5%) patients, independently of cutaneous subtype (44.6% in diffuse cutaneous systemic sclerosis vs 42.9% in limited cutaneous systemic sclerosis, p = 0.81). At least one microvascular complication was found in 108 (50.5%) patients: 105 (49.1%) with previous or current digital ulcers, 6 (2.8%) with renal crisis, and 4 (1.9%) with pulmonary arterial hypertension. Microvascular complications were more frequent in patients with elevated D-dimer (57.0% vs 45.5%, p = 0.09), significantly so after exclusion of patients with a history of cancer and/or venous thromboembolism (60.5% vs 44.8%, p = 0.04). Macrovascular complications were detected in 15 (7.0%) patients and were associated with a high D-dimer level (11.8% vs 3.3%, p = 0.03). Over a median follow-up of 2.3 years [1.1-3.3] after D-dimer measurement, new macrovascular complications occurred only in patients with high D-dimer (n = 8).
Conclusion:
High D-dimer levels are frequently found in systemic sclerosis patients and seem to be associated with the occurrence of macrovascular and microvascular complications after adjustment for confounding factors.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction

